Literature DB >> 9485192

Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts.

B Seliger1, C Harders, S Lohmann, F Momburg, S Urlinger, R Tampé, C Huber.   

Abstract

Malignant transformation is often associated with genetic alterations providing tumor cells with mechanisms for escape from immune surveillance. Human and murine tumors of various origin as well as in vitro models of viral and oncogenic transformation express reduced levels of major histocompatibility complex (MHC) class I antigens resulting in decreased sensitivity to MHC class I-restricted cytotoxic T lymphocyte (CTL)-mediated lysis. We here investigate whether the suppressed MHC class I surface expression of ras-transformed fibroblasts is due to dysregulation of the genes of the antigen-processing machinery, the peptide transporters TAP-1 and TAP-2 and the proteasome subunits LMP-2 and LMP-7, and whether it can be restored by gene transfer. In comparison to parental NIH3T3 cells, the ras oncogenic transformants revealed reduced TAP and LMP mRNA expression and impaired function of these genes, leading to deficient peptide transport and peptide loading of MHC class I molecules resulting in instable expression of the MHC class I complex on the cell surface. Enhanced H-2 surface expression due to stabilization of the MHC class I complex could be achieved by culturing ras transformants at low, unphysiological temperature (26 degrees C) or by loading these cells with either exogenous human beta2-microglobulin or MHC class I-binding peptide alone or in combination. Furthermore, interferon-gamma treatment was capable to enhance the expression of TAP, LMP and MHC class I molecules in both parental as well as ras-transformed fibroblasts. Stable transfection of the human TAP-1 cDNA into ras transformants caused a partial reconstitution of the peptide transport and an enhancement of the MHC class I surface expression, whereas the level of MHC class I biosynthesis was not affected by TAP-1 overexpression in parental cells. Together these results point to the existence of an association between oncogenic transformation and deficiencies in the MHC class I antigen-restricted immunosurveillance, suggesting intervention strategies involving specific MHC class I-binding peptides or transfection of the LMP and/or TAP genes to overcome the expression of the immune escape phenotype.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9485192     DOI: 10.1002/(SICI)1521-4141(199801)28:01<122::AID-IMMU122>3.0.CO;2-F

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  35 in total

1.  Tumoral environment triggers transcript anomalies in established tumors: induction of altered gene expression and of aberrant, truncated and B2 repeat-containing gene transcripts.

Authors:  P Rottiers; M Desmedt; H Dooms; R Contreras; J Grooten
Journal:  Neoplasia       Date:  1999-12       Impact factor: 5.715

Review 2.  Anti-HER2 vaccines: new prospects for breast cancer therapy.

Authors:  Maha Zohra Ladjemi; William Jacot; Thierry Chardès; André Pèlegrin; Isabelle Navarro-Teulon
Journal:  Cancer Immunol Immunother       Date:  2010-06-08       Impact factor: 6.968

3.  Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms.

Authors:  Marco Bezzi; Nina Seitzer; Tomoki Ishikawa; Markus Reschke; Ming Chen; Guocan Wang; Caitlin Mitchell; Christopher Ng; Jesse Katon; Andrea Lunardi; Sabina Signoretti; John G Clohessy; Jiangwen Zhang; Pier Paolo Pandolfi
Journal:  Nat Med       Date:  2018-01-08       Impact factor: 53.440

Review 4.  Cancer gene and immunotherapy: recent developments.

Authors:  P Jantscheff; R Herrmann; C Rochlitz
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

Review 5.  Elements of cancer immunity and the cancer-immune set point.

Authors:  Daniel S Chen; Ira Mellman
Journal:  Nature       Date:  2017-01-18       Impact factor: 49.962

6.  Covalent Guanosine Mimetic Inhibitors of G12C KRAS.

Authors:  Yuan Xiong; Jia Lu; John Hunter; Lianbo Li; David Scott; Hwan Geun Choi; Sang Min Lim; Anuj Manandhar; Sudershan Gondi; Taebo Sim; Kenneth D Westover; Nathanael S Gray
Journal:  ACS Med Chem Lett       Date:  2016-11-30       Impact factor: 4.345

Review 7.  Vaccines for established cancer: overcoming the challenges posed by immune evasion.

Authors:  Sjoerd H van der Burg; Ramon Arens; Ferry Ossendorp; Thorbald van Hall; Cornelis J M Melief
Journal:  Nat Rev Cancer       Date:  2016-03-11       Impact factor: 60.716

8.  Early treatment with metformin induces resistance against tumor growth in adult rats.

Authors:  Amanda B Trombini; Claudinéia Cs Franco; Rosiane A Miranda; Júlio C de Oliveira; Luiz F Barella; Kelly V Prates; Aline A de Souza; Audrei Pavanello; Ananda Malta; Douglas L Almeida; Laize P Tófolo; Kesia P Rigo; Tatiane As Ribeiro; Gabriel S Fabricio; Juliane R de Sant'Anna; Marialba Aa Castro-Prado; Helenir Medri de Souza; Hely de Morais; Paulo Cf Mathias
Journal:  Cancer Biol Ther       Date:  2015-05-29       Impact factor: 4.742

9.  Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinoma.

Authors:  T Maruyama; K Mimura; E Sato; M Watanabe; Y Mizukami; Y Kawaguchi; T Ando; H Kinouchi; H Fujii; K Kono
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

Review 10.  Signaling pathways involved in MDSC regulation.

Authors:  Prashant Trikha; William E Carson
Journal:  Biochim Biophys Acta       Date:  2014-04-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.